User menu

A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial

Bibliographic reference Morschhauser, Franck ; Fitoussi, Olivier ; Haioun, Corinne ; Thieblemont, Catherine ; Quach, Hang ; et. al. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. In: European Journal of Cancer, Vol. 49, no.13, p. 2869-2876 (2013)
Permanent URL http://hdl.handle.net/2078.1/175641